Esad Koklu1, Erdal Avni Ariguloglu2, Selmin Koklu3. 1. Department of Neonatology, Megapark Hospital, Kahramanmaraş, Turkey. Electronic address: esadsena@yahoo.com.tr. 2. Department of Obstetrics and Gynecology, Megapark Hospital, Kahramanmaras, Turkey. 3. Department of Pediatrics, Turkey Ministry of Health Necip Fazıl Hospital, Kahramanmaras, Turkey.
Abstract
BACKGROUND: Neonatal seizures are often refractory to treatment with initial antiseizure medications. Clinicians turn to agents such as levetiracetam despite the paucity of published data regarding its safety, tolerability, or efficacy in the neonatal population. PATIENT PRESENTATION: We describe a neonate who developed anaphylactic shock developing after receiving intravenous levetiracetam. RESULTS: This is the first neonate to develop anaphylactic shock due to intravenous administration of levetiracetam. CONCLUSION: Clinicians should be aware of this potentially fatal adverse effect occurring with intravenous levetiracetam in newborns.
BACKGROUND:Neonatal seizures are often refractory to treatment with initial antiseizure medications. Clinicians turn to agents such as levetiracetam despite the paucity of published data regarding its safety, tolerability, or efficacy in the neonatal population. PATIENT PRESENTATION: We describe a neonate who developed anaphylactic shock developing after receiving intravenous levetiracetam. RESULTS: This is the first neonate to develop anaphylactic shock due to intravenous administration of levetiracetam. CONCLUSION: Clinicians should be aware of this potentially fatal adverse effect occurring with intravenous levetiracetam in newborns.